Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Bioorganic and Medicinal Chemistry Letters is Scopus-indexed (Q2, CiteScore 4.5), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier Ltd.
Checked against the index lists dated .
ISSN 0960-894XVerify ISSN ↗1464-3405Verify ISSN ↗
Publisher: Elsevier Ltd
Cost to publish: About US$3,880 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmaceutical Science | 77 / 191 | 59th | Q2 |
| Organic Chemistry | 102 / 215 | 52nd | Q2 |
| Clinical Biochemistry | 63 / 124 | 49th | Q3 |
| Drug Discovery | 88 / 161 | 45th | Q3 |
| Biochemistry | 247 / 448 | 44th | Q3 |
| Molecular Biology | 254 / 414 | 38th | Q3 |
| Molecular Medicine | 118 / 179 | 34th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1991–present, best quartile Q2, CiteScore 4.5.
Bioorganic and Medicinal Chemistry Letters is Q2 in Pharmaceutical Science (rank 77 of 191), Q2 in Organic Chemistry (rank 102 of 215) and Q3 in Clinical Biochemistry (rank 63 of 124), by CiteScore 2025. It is ranked in 7 subject areas in all.
Bioorganic and Medicinal Chemistry Letters is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.5, which places it in quartile Q2 at the 59th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.426, quartile Q2, with an H-index of 177.
The publisher lists an article processing charge of about US$3,880 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Bioorganic and Medicinal Chemistry Letters is published by Elsevier Ltd. Its print ISSN is 0960-894X and its online ISSN is 1464-3405.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Bioorganic and Medicinal Chemistry Letters has an h-index of 181 and a 2-year mean of 2.26 citations per paper (OpenAlex). Its Scopus CiteScore is 4.5, quartile Q2. On 2-year citations it ranks #79 of 177 Scopus journals in Pharmaceutical Science.
Bioorganic and Medicinal Chemistry Letters published 363 papers in 2025; its busiest recent year was 2017 with 983. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 87 research articles (2026), authors are most often from China (37.9%), United States (18.2%) and India (11.5%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 31 retracted papers are recorded (1 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.